Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research
Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of...
top of page
NEWS & EVENTS
May 31
Lario Therapeutics invited to present at the CACNA1E International Family Conference
Munich, Germany, 21 May 2024: Lario Therapeutics CEO Henning Steinhagen and CSO Tom Otis were invited to the inaugural CACNA1E Family...
Nov 7, 2023
Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies
“CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum,...
bottom of page